

**Table S1. The clinical information of the patients enrolled in this study**


	<b>Name</b>	<b>Gender</b>	<b>Age (years)</b>	<b>Main Clinical Diagnosis</b>	<b>Operative Methods</b>	<b>PCAF Expression (optical density)</b>
1	<i>LM</i>	female	15	Complex cyanotic congenital heart disease	heart transplantation	0.264
2	<i>FJQ</i>	male	18	dilated cardiomyopathy	heart transplantation	0.268
3	<i>ZX</i>	male	30	dilated cardiomyopathy	heart transplantation	0.468
4	<i>ZYQ</i>	male	33	dilated cardiomyopathy	heart transplantation	0.273
5	<i>ZCQ</i>	male	34	dilated cardiomyopathy	heart transplantation	0.38
6	<i>ZJ</i>	male	35	dilated cardiomyopathy	heart transplantation	0.191
7	<i>CZH</i>	male	37	dilated cardiomyopathy	heart transplantation	0.231
8	<i>LYS</i>	male	38	dilated cardiomyopathy	heart transplantation	0.21
9	<i>ZWL</i>	male	40	dilated cardiomyopathy	heart transplantation	0.529

10	<i>ZC</i>	male	42	heart failure	heart-lung transplantation	0.426
11	<i>LSB</i>	male	42	dilated cardiomyopathy	heart transplantation	0.429
12	<i>WBJ</i>	male	42	ischemic cardiomyopathy	heart transplantation	0.354
13	<i>GMZ</i>	male	43	dilated cardiomyopathy	heart transplantation	0.506
14	<i>HXR</i>	female	43	ischemic cardiomyopathy	heart transplantation	0.561
15	<i>HFX</i>	male	44	ischemic cardiomyopathy	heart transplantation	0.736
16	<i>CJY</i>	male	45	ischemic cardiomyopathy	heart transplantation	0.587
17	<i>ZCH</i>	male	45	dilated cardiomyopathy	heart transplantation	0.697
18	<i>WLQ</i>	male	48	ischemic cardiomyopathy	heart transplantation	0.763
19	<i>HW</i>	male	48	ischemic cardiomyopathy	heart transplantation	0.769
20	<i>CHR</i>	male	49	Eisenmenger syndrome	heart transplantation	0.728
21	<i>LSX</i>	male	49	dilated cardiomyopathy	heart transplantation	0.703
22	<i>GXF</i>	male	49	dilated cardiomyopathy	heart transplantation	0.934

23	<i>WWY</i>	female	50	ischemic cardiomyopathy	heart transplantation	0.801
24	<i>RAM</i>	female	50	dilated cardiomyopathy	heart transplantation	0.794
25	<i>JWD</i>	male	51	ischemic cardiomyopathy	heart transplantation	0.905
26	<i>FDL</i>	male	52	dilated cardiomyopathy	heart transplantation	0.869
27	<i>CJY</i>	female	52	valvular heart disease	heart transplantation	0.825
28	<i>SSL</i>	female	52	dilated cardiomyopathy	heart transplantation	0.874
29	<i>LJX</i>	female	53	heart failure	heart transplantation	0.786
30	<i>ZDZ</i>	female	53	ischemic cardiomyopathy	heart transplantation	0.791
31	<i>XHK</i>	male	54	ischemic cardiomyopathy	heart transplantation	0.859
32	<i>MCX</i>	male	55	dilated cardiomyopathy	heart transplantation	0.874
33	<i>LGY</i>	male	56	dilated cardiomyopathy	heart transplantation	0.783
34	<i>WZY</i>	male	56	dilated cardiomyopathy	heart transplantation	0.907
35	<i>ZLF</i>	male	57	dilated cardiomyopathy	heart transplantation	0.74

36	<i>YWZ</i>	male	58	dilated cardiomyopathy	heart transplantation	0.869
37	<i>LJS</i>	male	59	dilated cardiomyopathy	heart transplantation	0.937
38	<i>CE</i>	male	59	dilated cardiomyopathy	heart transplantation	0.823
39	<i>YAP</i>	female	59	ischemic cardiomyopathy	heart transplantation	0.841
40	<i>ZYM</i>	male	59	ischemic cardiomyopathy	heart transplantation	0.874
41	<i>GSQ</i>	male	60	heart failure	heart transplantation	0.976
42	<i>SCR</i>	female	60	dilated cardiomyopathy	heart transplantation	0.713
43	<i>WKF</i>	female	60	dilated cardiomyopathy	heart transplantation	0.883
44	<i>ZQG</i>	male	61	dilated cardiomyopathy	heart transplantation	0.893

**Supplementary Figure S1**



**Supplementary Figure S1** The expression of Nrf2 and its downstream HO-1 and NQO1 in ECs decreased significantly after Nrf2 silencing. (A-B) Nrf2 small interfering RNA (siRNA) inhibits the expression of Nrf2 in ECs, detected by western blot (n=6). (C) Immunofluorescence detection of Nrf2 distribution in each group. The scale bar is 50 μm, 400× (n=3). (D-F) Western blot to determine the expression of HO-1 and

NQO1 in each group (n=6). <sup>#</sup> $p < 0.05$ , <sup>##</sup> $p < 0.01$  vs. AngII+Ad-GFP group; <sup>&</sup> $p < 0.05$ , <sup>&&</sup> $p < 0.01$  vs. the AngII induction with Ad-PCAF RNAi group (AngII+Ad-PCAF RNAi group); <sup>△</sup> $p < 0.05$  vs. the AngII induction with Ad-PCAF RNAi group and Nrf2 small interfering RNA (AngII+Ad-PCAF RNAi+si Nrf2 group).